Precision Optics (POCI) investor relations material

Executive summary

• Achieved record Q3 revenue of $8.7 million, up 108% year-over-year and 18% sequentially, driven by core production programs and operational improvements.

• Positive adjusted EBITDA reached for the first time at $0.3 million, reflecting improved manufacturing efficiency and cost controls.

• Net loss narrowed to $108,000 from $2.1 million a year ago and $1.8 million in the prior quarter.

• Strengthened balance sheet with an oversubscribed public offering in March 2026, raising $10–$10.6 million in net proceeds for growth initiatives.

• Increased full-year fiscal 2026 revenue and adjusted EBITDA guidance based on strong results and visibility.

Financial highlights

• Q3 revenue was $8.7 million, up 108% year-over-year and up from $7.4 million in the prior quarter.

• Gross margin improved to 23.6% from 10% a year ago and 2.8% in the prior quarter.

• Net loss per share improved to $(0.01) in Q3 from $(0.30) year-over-year.

• Cash and cash equivalents at March 31, 2026, were $10.7 million, up from $900,000 at December 31, 2025, and $1.8 million at prior year-end.

• Nine-month revenue was $22.8 million, up from $12.9 million year-over-year.

Outlook and guidance

• Fiscal 2026 revenue guidance raised to $29–$31 million (previously $26–$28 million), representing 52%–62% growth over fiscal 2025.

• Fiscal 2026 adjusted EBITDA guidance improved to -$2.5 million to -$2.7 million (previously -$2.5 million to -$3.0 million).

• Q4 expected to be roughly break-even on adjusted EBITDA.

• Management expects available cash, operations, and capital markets access to cover working capital and capital expenditures for at least 12 months.

• Anticipates continued strong performance from lead aerospace and cystoscope lines, with new programs ramping in fiscal 2027.